2024-2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Data are limited on 2024-2025 BNT162b2 COVID-19 vaccine effectiveness (VE).
Methods
Retrospective cohort study among non-immunocompromised adults from August 22, 2024 (“index”) to December 31, 2024, among residents of California or Louisiana continuously enrolled in health insurance plans reporting to HealthVerity for ≥1 year prior to index. Receipt of 2024-2025 BNT162b2 COVID-19 vaccine was defined using state vaccine registries with health insurance claims, using a time-varying exposure definition. VE against COVID-19-associated hospital admissions was estimated as (1-hazard ratio), using adjusted Cox proportional hazards models with 95% confidence intervals (CI).
Results
Overall, 6,900,361 individuals met selection criteria for the study. By the end of follow-up (median 4.4 months), 325,362 (4.7%) had received a BNT162b2 2024-2025 COVID-19 vaccine dose. VE against COVID-19-associated hospital admission was 41% (95% CI 2-64).
Discussion
The 2024-2025 formulation of BNT162b2 COVID-19 vaccine provided significant protection, particularly for older adults, in mid-season estimates.
This study is registered on clinicaltrials.gov as NCT06923137 .
